GWM
ESPR icon

Gupta Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

Gupta Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,000
Closed -$24K – 1281
2015
Q3 		$24K Buy
+1,000
New +$62.8K 0.01% 649

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Gupta Wealth Management's ESPR Position: Q4 2015 in Review

Gupta Wealth Management sold out of Esperion Therapeutics (ESPR) in Q4 2015, closing a stake of 1,000 shares — an estimated $24K sold.

Gupta Wealth Management first reported a position in ESPR in Q3 2015 and held it in 1 quarter. The position peaked at $24K in Q3 2015. 113 funds tracked by Wall St. Rank hold ESPR as of Q4 2015.

  • Gupta Wealth Management reported no remaining Esperion Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Gupta Wealth Management sold 1,000 Esperion Therapeutics shares in Q4 2015, an estimated $24K.
  • Gupta Wealth Management first reported a position in Esperion Therapeutics in Q3 2015 and held it in 1 quarter.
  • Gupta Wealth Management's Esperion Therapeutics position peaked at $24K in Q3 2015.
  • 113 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2015.

Based on Gupta Wealth Management's 13F filing for Q4 2015, filed 17 Feb 2016.